Additional Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia

被引：0
|
作者：
Satlin, Andrew [1 ]
Vanover, Kimberly [1 ]
Durgam, Suresh [1 ]
Mates, Sharon [1 ]
Davis, Robert [1 ]
Correll, Christoph [1 ]
机构：
[1] Intracellular Therapies Inc, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2019年 / 44卷 / SUPPL 1期
关键词：
Schizophrenia; Antipsychotics; Open Label Trials; Clinical Trial; Long-Term Safety;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
W203
引用
收藏
页码：493 / 494
页数：2
相关论文
共 50 条
  • [41] Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study (vol 239, pg 83, 2022)
    Filts, Yuriy
    Litman, Robert E.
    Martinez, Javier
    Anta, Lourdes
    Naber, Dieter
    Correll, Christoph U.
    [J]. SCHIZOPHRENIA RESEARCH, 2022, 246 : 258 - 259
  • [42] Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study
    Altamura, AC
    Salvadori, D
    Madaro, D
    Santini, A
    Mundo, E
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2003, 76 (1-3) : 267 - 271
  • [43] Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: A 12-month, open-label, flexible-dose, naturalistic observational trial
    Ratner, Yael
    Gibel, Anatoly
    Yorkov, Vladimir
    Ritsner, Michael S.
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (07): : 1401 - 1409
  • [44] The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
    Sommerauer, M.
    Doehn, C.
    [J]. ONKOLOGE, 2009, 15 (08): : 799 - 801
  • [45] The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
    Klotz, Laurence
    Boccon-Gibod, Laurent
    Shore, Neal D.
    Andreou, Cal
    Persson, Bo-Eric
    Cantor, Per
    Jensen, Jens-Kristian
    Olesen, Tine Kold
    Schroeder, Fritz H.
    [J]. BJU INTERNATIONAL, 2008, 102 (11) : 1531 - 1538
  • [46] Safety and efficacy of oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results of a 12-month interim analysis of the open-label phase from the EASE study
    Martinez, Anna
    Murrell, Dedee F.
    Bruckner, Anna L.
    Kern, Johannes
    Maher, Laura
    Cunningham, Tracy
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 89 - +
  • [47] Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
    Jason Aldred
    Eric Freire-Alvarez
    Alexander V. Amelin
    Angelo Antonini
    Bruno Bergmans
    Filip Bergquist
    Manon Bouchard
    Kumar Budur
    Camille Carroll
    K. Ray Chaudhuri
    Susan R. Criswell
    Erik H. Danielsen
    Florin Gandor
    Jia Jia
    Thomas E. Kimber
    Hideki Mochizuki
    Weining Z. Robieson
    Amy M. Spiegel
    David G. Standaert
    Saritha Talapala
    Maurizio F. Facheris
    Victor S. C. Fung
    [J]. Neurology and Therapy, 2023, 12 (6) : 1937 - 1958
  • [48] Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
    Adams, David
    Polydefkis, Michael
    Gonzalez-Duarte, Alejandra
    Wixner, Jonas
    Kristen, Arnt, V
    Schmidt, Hartmut H.
    Berk, John L.
    Losada Lopez, Ines Asuncion
    Dispenzieri, Angela
    Quan, Dianna
    Conceicao, Isabel M.
    Slama, Michel S.
    Gillmore, Julian D.
    Kyriakides, Theodoros
    Ajroud-Driss, Senda
    Waddington-Cruz, Marcia
    Mezei, Michelle M.
    Plante-Bordeneuve, Violaine
    Attarian, Shahram
    Mauricio, Elizabeth
    Brannagan, Thomas H., III
    Ueda, Mitsuharu
    Aldinc, Emre
    Wang, Jing Jing
    White, Matthew T.
    Vest, John
    Berber, Erhan
    Sweetser, Marianne T.
    Coelho, Teresa
    [J]. LANCET NEUROLOGY, 2021, 20 (01): : 49 - 59
  • [49] Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine
    Ford, Janet H.
    Foster, Shonda A.
    Stauffer, Virginia L.
    Ruff, Dustin D.
    Aurora, Sheena K.
    Versijpt, Jan
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2018, 12 : 2413 - 2424
  • [50] Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
    Christoph U. Correll
    Kenneth S. Koblan
    Seth C. Hopkins
    Yan Li
    Robert Heather Dworak
    Antony Goldman
    [J]. npj Schizophrenia, 7
12345